醒脑静注射液联合依达拉奉治疗急性脑出血临床观察

Clinical Effect of Xingnaojing Injection Combined with Edaravone in the Treatment of Acute Cerebral Hemorrhage and Its Influence on the Indexes of Oxidative Stress in Patients

目的研究探讨醒脑静注射液联合依达拉奉治疗急性脑出血的临床疗效及对氧化应激指标的影响。方法选取2018年3月-2020年3月期间医院接受治疗的94例急性脑出血患者为研究对象,随机分为观察组、对照组,各47例。对照组给予依达拉奉治疗,观察组在对照组基础上联合醒脑静注射液治疗。对两组临床疗效、认知功能评分、脑损伤标志物、氧化应激指标、不良反应发生率等进行统计比较。结果观察组总有效率91.49%(43/47),高于对照组74.47%(35/47),两组间疗效比较差异有统计学意义(P<0.05)。治疗后观察组神经功能缺损评分(NIHSS)低于对照组,格拉斯哥昏迷指数评分(GCS)、蒙特利尔认知功能评分(MoCA)均高于对照组(P<0.05)。治疗后观察组神经元特异性烯醇化酶(NSE)、胶质纤维酸性蛋白(GFAP)、血浆内皮素-1(ET-1)水平均低于对照组(P<0.05)。治疗后观察组超氧化物歧化酶(SOD)水平高于对照组,丙二醛(MDA)、8-异前列腺素(8-iPG)水平低于对照组(P<0.05)。治疗期间观察组、对照组不良反应发生率分别14.89%(7/47)、8.51%(4/47),组间比较差异无统计学意义(P>0.05)。结论醒脑静注射液联合依达拉奉治疗急性脑出血的临床疗效显著,能够改善认知功能,降低脑损伤标志物水平,改善机体的氧化应激水平,治疗安全性良好,值得临床推荐。

Objective To study the clinical effect of Xingnaojing injection combined with edaravone in the treatment of acute cerebral hemorrhage and its effect on oxidative stress index.Methods 94 patients with acute cerebral hemorrhage treated in our hospital from March 2018 to March 2020 were randomly divided into observation group and control group,47 cases each.The patients in the control group were treated with edaravone and the observation group were treated with Xingnaojing Injection on the basis of the control group.The clinical effect,cognitive function score,brain injury markers,oxidative stress index and adverse reactions rate of the two groups were compared.Results the total effective rate of the observation group was 91.49%(43/47),which was higher than that of the control group(74.47%).After treatment,NIHSS of the observation group was lower than that of the control group,GCS and MOCA were higher than that of the control group(P<0.05).The levels of NSE,GFAP and ET-1 in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of superoxide dismutase(SOD)and malondialdehyde(MDA)and 8-Isoprostaglandin(8-ipg)in the observation group were significantly higher than those in the control group(P<0.05).During the treatment,the incidence of adverse reactions in the observation group and the control group were 14.89%(7/47)and 8.51%(4/47),respectively.There was no significant difference between the two groups(P>0.05).Conclusion Xingnaojing injection combined with edaravone has a significant clinical effect in the treatment of acute cerebral hemorrhage.It can improve the cognitive function of patients,reduce the level of brain injury markers,improve the level of oxidative stress in the body,and has a good therapeutic safety,which is worthy of clinical recommendation.